ArticleJTO clinical and research reports2026
Clinical Outcomes for Patients who Received Both Trastuzumab Deruxtecan (T-DXd) and Trastuzumab Emtansine (T-DM1) for HER2-Mutant non-Small Cell Lung Cancer.
Daniel Reinhorn et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.